Andreas Humpe

Learn More
CD96, a cell surface antigen recently described to be preferentially expressed on acute myeloid leukemia (AML) leukemic stem cells (LSC) may represent an interesting target structure for the development of antibody-based therapeutic approaches. The v-regions from the CD96-specific hybridoma TH-111 were isolated and used to generate a CD96-specific single(More)
Acute myeloid leukemia (AML) is a clonal disorder preferentially affecting the blood and bone marrow and characterized by the accumulation of abnormally differentiated myeloid cells. Despite the existence of a variety of AML subgroups, AML seems to be organized hierarchically in at least three compartments: AML leukemic stem cells (LSCs), progenitor cells(More)
  • 1